Stockreport

Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026

Spyre Therapeutics, Inc.  (SYRE) 
PDF Recruitment for the rheumatoid arthritis (RA) sub-study of the SKYWAY basket trial is complete; Week 12 topline data now expected in Q3 2026 Recruitment for the psoriat [Read more]